![]() |
市场调查报告书
商品编码
1629887
全球单剂量鼻喷装置市场 - 2025-2033Global Single-Dose Nasal Spray Devices Market - 2025-2033 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
2023年,全球单剂量鼻喷装置市场达到3.355亿美元,预计2033年将达到5.371亿美元,2025-2033年预测期间复合年增长率为6.5%。
单剂量鼻喷剂是单位剂量装置,包含单一的、预先计量的药物剂量,使其在紧急情况下非常有用。它们允许患者或照护者施用救生药物,而无需专门培训或立即联繫医疗保健专业人员,例如传统上透过注射施用的鸦片类药物或纳洛酮。
驱动程式和限制
过敏性鼻炎的盛行率不断增加
由于过敏性鼻炎(一种会导致鼻塞、打喷嚏和搔痒的慢性疾病)盛行率不断上升,全球单剂量鼻喷装置市场正在成长。这些设备提供了一种方便、有针对性的方法,可实现精确剂量和最小化副作用,这使得它们对于控制病情至关重要。随着人们对过敏性鼻炎的认识不断提高以及患者寻求更有效的治疗方案,对先进鼻喷装置的需求持续增长。创新配方的出现进一步支持了这个趋势。
例如,根据世界过敏组织杂誌的报导,全球过敏性鼻炎影响超过 4 亿人,成人的盛行率在 10% 至 30% 之间,儿童的盛行率超过 40%。
因此,单剂量鼻喷装置因其易于使用、剂量精确且作用迅速而成为治疗过敏性鼻炎症状的理想选择。它们的广泛流行推动了对这些设备的需求,鼓励对先进药物配方和设备技术的创新和投资,从而推动市场扩张。
患者误用和不当给药的风险
由于患者误用和给药不当的风险,全球单剂量鼻喷雾装置市场面临挑战。这些设备需要精确的操作和应用技术,这对于不熟悉它们的患者来说可能具有挑战性,尤其是儿童和老年人群。缺乏强有力的患者教育和培训计划进一步加剧了这个问题,导致潜在的剂量不足或浪费。此外,单剂量设备被认为比多剂量替代品产生更多的医疗废弃物,引发了环境问题,并阻碍了废弃物管理政策严格的地区的采用。这些挑战阻碍了市场成长,并强调需要更好的设计创新和患者支援计划。
The global single-dose nasal spray devices market reached US$ 335.5 million in 2023 and is expected to reach US$ 537.1 million by 2033, growing at a CAGR of 6.5% during the forecast period 2025-2033.
Single-dose nasal sprays are unit-dose devices that contain a single, pre-measured dose of medication, making them useful in emergency settings. They allow patients or caregivers to administer life-saving medications without requiring specialized training or immediate access to healthcare professionals, such as opioids or naloxone, which are traditionally administered via injection.
Market Dynamics: Drivers & Restraints
Increasing Prevalence of Allergic Rhinitis
The global single-dose nasal spray devices market is growing due to the rising prevalence of allergic rhinitis, a chronic condition causing nasal congestion, sneezing, and itching. These devices offer a convenient, targeted method for precise dosing and minimal side effects, making them essential for managing the condition. As awareness of allergic rhinitis increases and patients seek more efficient treatment options, demand for advanced nasal spray devices continues to rise. The availability of innovative formulations further supports this trend.
For instance, according to World Allergy Organization Journal, Globally, allergic rhinitis affects more than 400 million people, with prevalence rates between 10% and 30% among adults and over 40% among children.
Hence, Single-dose nasal spray devices are ideal for managing allergic rhinitis symptoms due to their ease of use, precise dosing, and rapid action. Their widespread prevalence drives demand for these devices, encouraging innovation and investments in advanced drug formulations and device technologies, thereby fueling market expansion.
Risk of Misuse and Improper Administration by Patients
The global single-dose nasal spray device market faces challenges due to the risk of misuse and improper administration by patients. These devices require precise handling and application techniques, which can be challenging for patients unfamiliar with them, especially in pediatric and elderly populations. The lack of robust patient education and training programs further exacerbates this issue, leading to potential underdosing or wastage. Additionally, single-dose devices are perceived to generate more medical waste than multi-dose alternatives, raising environmental concerns and deterring adoption in regions with strict waste management policies. These challenges hinder market growth and underscore the need for better design innovation and patient support initiatives.
The global single-dose nasal spray devices market is segmented based on product type, material type, end user and region.
Liquid Nasal Sprays segment is expected to dominate the single-dose nasal spray devices market share
The liquid nasal sprays segment holds a major portion of the single-dose nasal spray devices market share and is expected to continue to hold a significant portion of the single-dose nasal spray devices market share during the forecast period.
Liquid nasal sprays are a key segment in the global single-dose nasal spray devices market due to their widespread use in various therapeutic areas, including allergic rhinitis, sinusitis, and emergency treatments like opioid overdose reversal. These sprays are preferred for their rapid onset of action, precision dosing, and ease of use, making them ideal for home-based and outpatient care. Advancements in liquid formulation technology have improved the stability and bioavailability of active ingredients, driving demand for innovative single-dose devices. The increasing adoption of liquid nasal sprays for vaccines and biologics further positions them as a key segment in the market.
Hospitals segment is the fastest-growing segment in single-dose nasal spray devices market share
The hospitals segment is the fastest-growing segment in the single-dose nasal spray devices market share and is expected to hold the market share over the forecast period.
Hospitals are driving the global single-dose nasal spray devices market growth due to their precision, ease of use, and effectiveness in acute care scenarios. These devices are ideal for emergency departments and critical care units, where timely intervention is crucial. Hospitals are often the first point of contact for patients with chronic conditions, leading to the prescription and adoption of single-dose nasal sprays for ongoing treatment. The growing emphasis on infection control in healthcare facilities further bolsters the demand for single-dose devices, as they reduce the risk of cross-contamination compared to multi-dose alternatives. As hospitals adopt advanced drug delivery technologies, their role in shaping the market trajectory continues to expand.
North America is expected to hold a significant position in the single-dose nasal spray devices market share
North America holds a substantial position in the single-dose nasal spray devices market and is expected to hold most of the market share due to the FDA approvals, product launches, high prevalence of respiratory and allergic conditions, as well as its well-established healthcare infrastructure. The region's focus on self-care and home-based treatments, coupled with widespread patient awareness, drives demand for these devices. Regulatory approvals and investment from leading pharmaceutical companies contribute to the region's growth. Government initiatives to combat opioid overdoses have also accelerated the adoption of single-dose nasal sprays for emergency treatments.
For instance, in August 2024, The U.S. FDA has approved neffy, an epinephrine nasal spray, for emergency treatment of Type I allergic reactions in adult and pediatric patients weighing at least 30 kilograms. Neffy is a single-dose nasal spray used to treat anaphylactic episodes. If symptoms persist or worsen, a second dose may be administered using a new nasal spray. Patients may need emergency medical assistance for monitoring and treatment if further treatment is needed.
Europe is growing at the fastest pace in the single-dose nasal spray devices market
Europe holds the fastest pace in the single-dose nasal spray devices market and is expected to hold most of the market share due to the chronic respiratory diseases, aging populations, and environmental allergen exposure. Advanced healthcare systems, patient-friendly treatment options, and a preference for minimally invasive therapies have boosted the adoption of these products. Strong regulatory frameworks and supportive policies for drug delivery innovations encourage market growth. Europe's commitment to sustainability has led to the development of eco-friendly and biodegradable nasal spray devices, aligning with consumer preferences. Europe's emphasis on preventive healthcare and high-quality medical products further strengthens its market position.
For instance, according to article published in ERS, the UK experiences 585,000 respiratory disease diagnoses annually, with half due to asthma and COPD. IPF prevalence is double previous estimates. Nearly 1 in 5 of the population has a lung disease diagnosis, with the highest prevalence in the North-West and South-West of England. This widespread prevalence also drives innovation and adoption of advanced single-dose nasal sprays for chronic and acute respiratory disease management, contributing to the overall growth of the market in Europe and beyond.
The major global players in the single-dose nasal spray devices market include Aptar Pharma, Nemera, BD (Becton, Dickinson and Company), H&T Presspart, Bespak by Recipharm, Rexam Healthcare Packaging, Silgan Dispensing Systems, West Pharmaceutical Services, Inc, Gerresheimer AG, 3M Drug Delivery Systems and among others.
Emerging Players
The emerging players in the single-dose nasal spray devices market include Portal Instruments, E3D (Engineered 3D), Medicon Pharma, Perlen Packaging and among others.
The global single-dose nasal spray devices market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.
LIST NOT EXHAUSTIVE